Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression

Antibody-dependent cellular phagocytosis (ADCP) by monocytes and macrophages contributes significantly to the efficacy of many therapeutic monoclonal antibodies (mAbs), including anti-CD20 rituximab (RTX) targeting CD20+ B-cell non-Hodgkin lymphomas (NHL). However, ADCP is constrained by various imm...

Full description

Saved in:

Bibliographic Details
Main Authors:	Oanh T. P. Nguyen, Sandra Lara, Giovanni Ferro, Matthias Peipp, Sandra Kleinau
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	anti-CD20 antibody apoptosis CD47 cancer immunotherapy monocyte phagocytosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483617/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

Facilitating cholangiocarcinoma inhibition by targeting CD47
by: Kulthida Vaeteewoottacharn, et al.
Published: (2024-12-01)

An integrated “Engage & Evasion” approach for mononuclear phagocyte system escape and efficient extracellular vesicle therapy
by: Hongman Liu, et al.
Published: (2024-12-01)

The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma
by: Asim Armagan Aydin, et al.
Published: (2024-11-01)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
by: Jian‐Hua Wang, et al.
Published: (2019-03-01)

CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis
by: Yunmi Ko, et al.
Published: (2024-11-01)

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies
by: Malgorzata Bobrowicz, et al.
Published: (2024-12-01)

Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response
by: Qian Gou, et al.
Published: (2025-02-01)

The influence of probiotic administration on the phagocytic and oxidative burst activity of neutrophils and monocytes in the peripheral blood of dairy cows during different lactation periods
by: Brodzki Piotr, et al.
Published: (2024-08-01)

AFP shields hepatocellular carcinoma from macrophage phagocytosis by regulating HuR-mediated CD47 translocation in cellular membrane
by: Yinglian Pan, et al.
Published: (2025-02-01)

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01)

Blocking ANGPTL3 and CD47 impact on atherosclerosis-correspondence
by: Han-Yong Hou, et al.
Published: (2025-02-01)

The role of CD47 in immune escape of colon cancer and its correlation with heterogeneity of tumor immune microenvironment
by: Qiu-Si Tian, et al.
Published: (2024-12-01)

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
by: Federica Malighetti, et al.
Published: (2024-12-01)

Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
by: Ramazan Oguz Yüceer, et al.
Published: (2025-01-01)

Investigation of CD47 Expression in Renal Cell Tumors and Evaluation of Its Relationship with Prognostic Parameters
by: Ömer Faruk Dizibüyük, et al.
Published: (2024-12-01)

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma
by: Aiping Lin, et al.
Published: (2024-12-01)

NRF-1 transcription factor regulates expression of an innate immunity checkpoint, CD47, during melanomagenesis
by: Kuldeep Makwana, et al.
Published: (2024-12-01)

Bioengineer mesenchymal stem cell for treatment of glioma by IL‐12 mediated microenvironment reprogramming and nCD47‐SLAMF7 mediated phagocytosis regulation of macrophages
by: Man Li, et al.
Published: (2024-12-01)

Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation
by: Xiaozhi Hu, et al.
Published: (2024-12-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

IgM Flare in Anti-MAG Neuropathy Post Rituximab Treatment: A Clinical Case and a Systematic Review of the Literature
by: Giovanni Siconolfi, et al.
Published: (2024-12-01)

SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW
by: Francesca Pavanello, et al.
Published: (2016-11-01)

The origin of human CD20+ T cells: a stolen identity?
by: Marina Rode von Essen, et al.
Published: (2024-11-01)

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
by: Chunmei Yang, et al.
Published: (2024-11-01)

Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide
by: Jing Wang, et al.
Published: (2024-09-01)

Modulation of Monocyte Effector Functions and Gene Expression by Human Cytomegalovirus Infection
by: Matthew S. Planchon, et al.
Published: (2024-11-01)

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
by: Jeremy Loyau, et al.
Published: (2025-12-01)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01)

Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient
by: Gabriele Magliano, et al.
Published: (2021-08-01)

PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1)
by: Michele Bibas
Published: (2024-01-01)

Platelet activation through CD62P and the formation of platelet–monocyte complexes are associated with the exacerbation of mucosal inflammation in patients with ulcerative colitis
by: Yasuki Sano, et al.
Published: (2024-11-01)

A rare case of CD20− primary cutaneous diffuse large B-cell lymphoma, leg type
by: Juliette M. Kersten, MD, et al.
Published: (2024-12-01)

Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38
by: Knut Husø Lauritzen, et al.
Published: (2025-01-01)

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions
by: Michelle L. McKeague, et al.
Published: (2024-10-01)

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade
by: Junjie Li, et al.
Published: (2025-01-01)

CB2R activation enhances tumor-associated macrophages-mediated phagocytosis of glioma cell
by: Siyuan Lu, et al.
Published: (2024-12-01)

Clinical significance of unexpected antibody from IgG1 and IgG3 subtypes
by: LI Zhu, et al.
Published: (2024-11-01)

Anti-tumor and anti-metastatic effects of RRx-001 on hepatocellular carcinoma: mechanisms of action and therapeutic potential
by: Guohong Yan, et al.
Published: (2024-11-01)